Background {#Sec1}
==========

Coronary heart disease (CHD) and in particular myocardial infarction (MI) is a major cause of morbidity, mortality and health expense worldwide \[[@CR1]\]. Up to 70 % of CHD incidence can be explained by individual-level sociodemographic characteristics (age, sex, socioeconomic status (SES)); health behaviors (smoking, physical inactivity, poor diet); and metabolic risk factors (hypertension, diabetes, hypercholesterolemia) \[[@CR2]\]. Today, CHD prevention includes both primary and secondary prevention with lifestyle changes as well as medical treatment of risk factors, primarily hypertension, diabetes, and hypercholesterolemia. HMG CoA-reductase inhibitors, or statins, are a class of cholesterol lowering drugs that are widely used in this context, in particular for secondary prevention of MI \[[@CR3]\]. Statins reduce both mortality and morbidity for CHD patients \[[@CR4]\].

Although individual-level sociodemographic characteristics, such as low individual SES, are important risk factors for CHD incidence, recent work has also shown that low neighborhood SES is associated with an increased risk of CHD, after adjustment for individual SES \[[@CR5]--[@CR9]\].

However, no study has examined whether neighborhood SES is associated with statin medication rates, after taking individual socioeconomic factors into account. Such studies are important because if there are differences in statin medication by certain neighborhood-level characteristics, interventions will need to target such neighborhoods.

Sweden is a suitable setting for such a study because it is a country which has universal health coverage for all residents and good availability of health-related resources \[[@CR10]\]. It is therefore possible to examine whether statin medication patterns differ, by both individual and neighborhood level SES, in a country that has almost equal availability of health care.

The aim of this study is to determine whether the statin medication rates for MI patients differ across neighborhoods with different levels of neighborhood SES, after taking individual factors into account.

Methods {#Sec2}
=======

All data were linked by the personal Swedish identification number, which was replaced by a serial number in the dataset in order to maintain anonymity for all individuals. Health care data were retrieved from nationwide Swedish in-patient as well as out-patient specialist care; the latter in order to increase the number of cases as well as generalizability of findings. The Swedish Hospital Discharge Register contains nationwide hospital main and secondary discharge diagnoses encoded in the International Classification of Diseases (ICD) format. The tenth revision (ICD-10) has been in use since 1997 \[[@CR11]\]. The diagnoses in the Hospital Discharge Register have a positive predictive value between 85 and 95 %, and the validity of many cardiovascular diseases are even higher; e.g., MI, angina pectoris and atrial fibrillation have a positive predictive value of \> 95 % \[[@CR11]--[@CR13]\]. Since 2000, the proportion of missing primary diagnoses has been only 0.5--0.9 % \[[@CR11]\].

Inclusion criteria was MI registered as the main diagnosis in the Hospital Discharge Register or Outpatient Register within the study interval (2000 to 2010) using ICD-10 codes I21, I22, and I23. Only patients who previously had no CHD were included. This was achieved by excluding patients with a recorded main or secondary diagnosis of CHD (ICD-10 I20-I25) during a 3-year period, i.e., from 1997 to 1999, before study start. Patients, who died between 1 January 2000 and 30 June 2005, were excluded as medication data was not available for this time period. Also, all patients who died within one month of MI diagnosis were excluded, as we assumed that some of them might not have had a chance to pick up the medication. Patients above 80 years of age were excluded as the proportion of patients aged 80+ with statin medication was low.

Outcome (dependent) variable {#Sec3}
----------------------------

The outcome variable of medication of statins was defined according to the ATC code C10AA for the Medication Register.

The statins (HMG CoA reductase inhibitors, code C10AA) included were:C10AA01 SimvastatinC10AA02 LovastatinC10AA03 PravastatinC10AA04 FluvastatinC10AA05 AtorvastatinC10AA06 CerivastatinC10AA07 RosuvastatinC10AA08 Pitavastatin

Individual-level variables {#Sec4}
--------------------------

The individual-level variables used in models were sex, age at the start of the study, marital status, family income, education level, country of origin, urban/rural status, and chronic conditions related to MI (comorbidities) \[[@CR14]--[@CR16]\].

*Sex*: Male or female.

*Age* was assessed at start of follow-up. Age was used as a continuous variable in the models.

*Marital status*: Individuals were classified as married/cohabitating or widowed/divorced/never married.

*Family income by quartile*: Information on family income in 2001 came from the Total Population Register, provided by Statistics Sweden. Income was categorized into quartiles: low income, middle-low income, middle-high income, and high income. The income was divided by the number of people in the family. A weighted system was also used; small children were given lower weights than adolescents since the costs of living for a small child are lower than those for an adolescent.

*Education level* was classified as completion of compulsory school or less (≤9 years), vocational high school or some theoretical high school (10--12 years), and completed theoretical high school and/or college (\>12 years).

*Country of origin*: Born in: 1) Sweden (reference), 2) Finland, 3) Western countries, 4) Eastern European countries, 5) Middle Eastern countries, or 6) other countries. *Urban/rural status*: Residence in major cities (Stockholm, Gothenburg or Malmö), southern or northern Sweden.

*Chronic conditions related to MI\--comorbidities* were defined as the first diagnosis (main or additional diagnosis) ten years before the study and during the follow-up period of: 1) chronic lower respiratory diseases (ICD-9: 490--496; ICD-10: J40-J49), 2) alcoholism and alcohol-related liver disease (ICD-9: 291, 303, and 571; ICD-10: F10 and K70), 3) hypertension (ICD-9: 401--405; ICD-10: I10-I19), and 4) diabetes mellitus (ICD-9: 250; ICD-10: E10-E14).

Neighborhood-level socioeconomic status (SES) {#Sec5}
---------------------------------------------

The home addresses of all Swedish individuals have been geocoded to small geographical units that have boundaries defined by homogeneous types of buildings. These neighborhood areas, developed by Statistics Sweden, are called small areas for market statistics (SAMS) and have an average of 1000 people each. SAMS were used as proxies for neighborhoods, as in previous research \[[@CR7], [@CR17]\]. A summary index was calculated to characterize neighborhood-level SES \[[@CR5]\]. The neighborhood index was based on information on men and women aged 20--64, who lived in the neighborhood, because people in this age group are the most socioeconomically active. In other words, as a population group they have a stronger impact on the socioeconomic structure of the neighborhood than children, younger men/women and retirees. The neighborhood index was based on four items: low education level (\<10 years of formal education), low income (income from all sources, including that from interest and dividends, defined as less than 50 % of the median individual income), unemployment (excluding full-time students, those completing compulsory military service, and early retirees) and receipt of social welfare. The index was categorized into the following three groups: low neighborhood SES (more than 1 SD below the mean), middle neighborhood SES (within 1 SD of the mean), and high neighborhood SES (more than 1 SD above the mean) \[[@CR5]\]. The neighborhood SES index in the year 2000 was used in the models.

Statistical methods {#Sec6}
-------------------

Multilevel (hierarchical) logistic regression models were used to estimate odds ratios (OR) for statin medication rates for different levels of neighborhood SES. The analyses were performed using MLwiN version 2.27. The first model only included neighborhood-level SES to determine the crude odds of statin medication by level of neighborhood SES (Model 1). The second model also included the individual-level characteristics age and sex (Model 2). The third model added family income, marital status, country of origin, educational attainment and urban/rural status (Model 3). Last, a full model was created which also included hospitalization due to chronic lower respiratory disease, alcoholism and related liver disease, type 2 diabetes mellitus or hypertension (Model 4, not shown in tables).

### Random effects {#Sec7}

The between-neighborhood variance was estimated with a random intercept. It was regarded to be significant if it was more than 1.96 times the size of the standard error, in accordance with the precedent set in previous studies \[[@CR18]--[@CR20]\].

We computed the intraclass correlation (ICC)---that is, the intra-neighborhood correlation---in order to estimate to what extent the individual chance of statin medication for individuals, within the same SAMS, was similar compared with individuals in other SAMS areas. The ICC expresses the proportion of the total variance that is at the neighborhood level. The ICC in multilevel logistic regression can be estimated by different procedures. We applied the latent variable method \[[@CR21]\] as exemplified by:$$\documentclass[12pt]{minimal}
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where Vn is the variance between neighborhoods and π^2^/3 is the variance between individuals.

The proportion of the second level variance explained by the different variables was calculated as:$$\documentclass[12pt]{minimal}
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where Vo is the age adjusted variance in the initial model and V~1~ is the second level variance in the different models.

First order interactions between neighborhood deprivation and individual-level characteristics for statin medication in MI patients were also analyzed.

For comparison, we also calculated logistic regression models using the SAS statistical package (version 9.3; SAS Institute, Cary, NC, USA).

Results {#Sec8}
=======

Table [1](#Tab1){ref-type="table"} shows the distribution of the study population and number of patients receiving statins by neighborhood-level SES. For statin medication, the number (No) of patients receiving statins as well as the share of patients on statin medication within each patient group (%) is presented. Of the 116,840 patients with MI included in this study, 104,766 (89.7 %) received statins during the study period. Of the total population, 19 %, 62 %, and 19 % lived in high, middle, and low SES neighborhoods, respectively. Age-standardized statin medication rates was 90.6 % in neighborhoods with high SES; 89.7 % in neighborhoods with middle SES; and 88.6 % in neighborhoods with low SES. This slight difference in statin medication rate by neighborhood-level SES was observed across all individual-level variables, as shown in Table [1](#Tab1){ref-type="table"}.Table 1Distribution of study population (patients with myocardial infarction, MI), number of statin medication events, and age-standardized rates by neighborhood socioeconomic status (SES)PopulationDistributionStatin medicationNeighborhood SES(%)No.%HighMiddleLowTotal population (%)116,84022,172 (19 %)72,655 (62 %)22,013 (19 %)Statin medication104,76689.790.689.788.6Sex Men80,35168.873,22391.191.890.689.0 Women36,48931.231,54386.487.587.687.4Age (years)  \< 5018,62315.917,18592.392.192.591.7 50--5934,00929.132,14794.595.194.693.6 60--6940,03434.336,78691.992.392.190.8 70--7924,17420.718,64877.178.677.474.8Educational attainment  ≤ 955,06147.147,81386.889.588.987.9 10--1231,69927.129,14791.991.291.289.5  \> 1230,08025.727,80692.492.291.389.9Marital status Married/cohabiting71,10860.964,92391.391.691.491.0 Never married, widowed, or divorced45,73239.139,84387.188.487.185.9Family income Low income29,29825.125,20186.088.187.787.5 Middle--low income29,17525.025,53887.589.189.187.2 Middle--high income29,20225.026,81291.890.891.090.5 High income29,16525.027,21593.392.191.691.7Country of origin Sweden99,94785.589,58189.690.689.888.5 Finland51134.4456889.390.488.287.0 Western countries13791.2123589.691.288.990.6 Eastern European countries25002.1231092.490.790.689.8 Middle Eastern countries24692.1228792.688.188.990.1 Others54324.6478588.189.388.486.5Urban/rural status Large cities52,57245.046,82989.190.189.087.6 Southern Sweden41,90735.938,12591.092.290.990.4 Northern Sweden22,36119.119,81288.689.588.787.7

Table [2](#Tab2){ref-type="table"} shows the age-adjusted ORs for each covariate. Patients with low family income had significantly lower odds of statin medication (OR 0.49) compared to patients with high family income. Low educational attainment was also associated with lower odds of statin medication (OR 0.71) compared to patients with high educational attainment.Table 2Odds ratios (OR) and 95 % confidence intervals (CI) for statin medication in patients with myocardial infarction; Results of multi-level logistic regression models for each variable, adjusted for ageOR95 % CIVariance (S.E.)*Explained variance (%)Intra class correlation*Neighborhood-level Socioeconomic status (SES, ref. High)0.068 (0.011)220.020 Middle0.930.880.98 Low0.790.740.84Sex (ref. Female)1.391.341.450.072 (0.011)170.021Family income (ref. High income)0.077 (0.011)110.023 Low income0.490.470.52 Middle-low income0.590.560.63 Milddle-high income0.840.790.89Marital status (ref. Married/co-habiting)0.060 (0.011)310.018 Never married, widowed, or divorced0.590.570.62Country of origin (ref. Born in Sweden)0.075 (0.011)140.022 Finland0.900.820.99 Western countries1.060.891.26 Eastern European countries1.100.941.28 Middle eastern countries0.990.841.16 Others0.800.740.88Educational attainment (ref. \> 12 years)0.075 (0.011)140.022  ≤ 9 years0.710.670.74 10--12 years0.920.870.98Urban/rural status (ref. large cities)0.059 (0.011)320.018 Southern Sweden1.281.221.34 Northern Sweden0.980.931.03

Table [3](#Tab3){ref-type="table"} shows the results of the different multilevel logistic regression models. In the crude model (Model 1), the odds of statin medication were lower for patients living in neighborhoods with low SES. The OR for statin medication in patients with MI living in neighborhoods with low compared to high neighborhood-level SES was 0.80 (95 % confidence interval (CI) 0.75--0.86). In Model 2, neighborhood-level SES remained significantly associated with statin medication after adjustment for age and sex (OR 0.80, 95 % CI 0.75--0.86).Table 3Odds ratios (OR) and 95 % confidence intervals (CI) for statin medication in patients with myocardial infarction; Results of multi-level logistic regression modelsModel 1Model 2Model 3OR95 % CIOR95 % CIOR95 % CINeighborhood-level socioeconomic status (SES, ref. High) Middle0.900.860.950.940.890.991.071.011.130.016 Low0.800.750.860.800.750.861.030.961.100.368Age (years)0.950.950.950.960.960.96\<0.001Sex (ref. Female)1.391.331.441.231.191.29\<0.001Family income (ref. High income) Low income0.490.460.52\<0.001 Middle-low income0.620.580.65\<0.001 Milddle-high income0.830.780.89\<0.001Marital status (ref. Married/co-habiting) Never married, widowed, or divorced0.610.580.63\<0.001Country of origin (ref. Born in Sweden) Finland1.020.931.120.689 Western countries1.070.891.270.484 Eastern European countries1.331.141.55\<0.001 Middle eastern countries1.331.131.56\<0.001 Others0.920.841.000.046Educational attainment (ref. \> 12 years)  ≤ 9 years0.890.840.94\<0.001 10--12 years1.131.061.21\<0.001Urban/rural status (ref. large cities) Southern Sweden1.301.241.37\<0.001 Northern Sweden1.020.971.080.424Variance (S.E.)0.082 (0.011)0.067 (0.011)0.053 (0.011)Explained variance (%)62339Intra class correlation0.0240.0200.016Model 1. Crude model; Model 2: Adjusted for age and sex; Model 3: Adjusted for age, sex, and individual socioeconomic variables

However, in the third model, after adding individual-level sociodemographic variables, the ORs no longer remained significant. The fourth model also included the variables for comorbidities, which did not change the ORs further, and the results are therefore not shown.

The between-neighborhood variance was significant in all models. The explained variance was 6 % in Model 1, indicating that the neighborhood variable explained only a small proportion of the total variance, and increased to 23 % in Model 2 and 39 % in Model 3.

The ICC was low, varying between 1.6 and 2.4 % in the different models, indicating that the clustering within neighborhoods was low.

Analyzing first order interactions between neighborhood SES and individual-level characteristics for statin medication in MI patients showed significant interactions between neighborhood level SES and education level only. The results of this analysis are shown in Additional file [1](#MOESM1){ref-type="media"}: Table S1.

Discussion {#Sec9}
==========

The present study shows that MI patients living in low SES neighborhoods had 20 % lower odds of statin medication compared to those living in middle and high SES neighborhoods. However, the odds no longer remained significant after adjusting for the individual-level sociodemographic characteristics and comorbidities. To the best of our knowledge, the potential influence of neighborhood SES on statin use in MI patients has not been examined previously.

Previous studies have shown that statin medication rates in CHD patients may vary due to individual-level factors such as the patients' age and comorbidities. In addition, low individual-level SES may affect medication patterns negatively \[[@CR22]--[@CR25]\] and it has been shown that when a larger proportion of the medication costs are required from the patients, statin utilization decreases, in particular for less regularly compliant patients \[[@CR26]\]. Individuals in neighborhoods with low SES are likely to have small financial margins \[[@CR27]\], which might affect their willingness to pay for prescribed drugs. The findings of the present study indicate that the lower odds of statin medication in MI patients living in deprived neighborhoods may be explained by individual-level socioeconomic factors. This could imply that the neighborhood in itself does not affect statin medication in this patient group.

Although the present study was unable to detect a neighborhood effect on statin medication in CHD patients, previous studies have shown that neighborhood-level deprivation is a strong predictor for CHD incidence and fatality from CHD after adjusting for individual-level sociodemographic characteristics \[[@CR5]\]. In addition, a recent study of ours has shown that neighborhood-level deprivation affects prescription patterns of statins in patients with atrial fibrillation, after adjusting for individual-level factors \[[@CR28]\]. Adults with atrial fibrillation living in high SES neighborhoods were more often prescribed statins (men and women, OR 1.23) compared to their counterparts residing in middle SES neighborhoods \[[@CR28]\]. It is unclear why neighborhood-level deprivation affects statin medication for patients with atrial fibrillation, but not for the MI patients in the present study.

One possible explanation could be that statin medication after MI is initiated almost exclusively at the hospital, i.e., in immediate relation to the event, whereas statin medication, for other reasons, might be initiated at a local health care center where the potential neighborhood effects may be stronger than in hospitals that cover a wider geographic area. Previous research has shown that prescription patterns among doctors working in local health care centers may be affected by neighborhood SES \[[@CR29]\]. Additionally, individuals living in more affluent neighborhoods may be better informed as patients, irrespective of individual-level SES.

Finally, differences in medication patterns may in some cases be explained by "medication deserts", where pharmacies in low SES neighborhoods may have lower availability of drugs \[[@CR30]\]. In Sweden, with universal health care and good availability of drugs, this is unlikely a problem.

The results of the current study, including all MI patients in Sweden during the study period, show that statin medication rates for these patients are generally high. Of the 116,840 patients with MI, 89.7 % received statins. For comparison, 89 and 88 % of patients were treated with statins according to Italian data from the REAL registry \[[@CR31]\] and French data from the FAST-MI registry \[[@CR32]\], respectively.

In the US, several studies of statin medication for CHD patients have shown medication rates of about 60-70 % \[[@CR33]--[@CR35]\]. However, those studies only included a sub-set of MI patients, and the authors of one of the studies that reported high medication rates explained their findings as a result of only including highly motivated medical practices \[[@CR36]\]. It has previously been shown that in countries without universal health insurance, lack of individual health insurance is associated with lower likelihood of being treated with a statin \[[@CR35], [@CR36]\]. It is also possible that availability of generic statins will result in lower costs for the patients and improved compliance. The high statin medication rates in this study indicates that universal health care may improve statin medication for MI patients, which could be an argument in support of providing universal health care to the entire population.

Limitations and strengths {#Sec10}
-------------------------

Our study has some limitations. Residual confounding may exist as socioeconomic measures only represent proxies for individual-level status. However, as the lower odds of statin medication in those MI patients living in deprived neighborhoods no longer remained significant after the statistical adjustments, it is likely that our socioeconomic measures are relatively good proxies of individual-level socioeconomic status. Another limitation is that we did not account for mobility, i.e., move to a different neighborhood during the follow-up period. However, we have previously checked the mobility in this age group and found it to be low. In addition, the follow-up period was relatively short, which implies that most people likely remained in their neighborhood during the study period.

This study has also, however, several strengths. The large cohort, which included practically all patients diagnosed with MI in Sweden during the study period, increases the generalizability of our results as very little data is missing. Another strength is the use of personal identification numbers, which made it possible to link health care data to socioeconomic data as well as following individuals in different national registers. A further strength is the use of the Hospital Discharge Register, which has high validity, especially for cardiovascular disorders \[[@CR11]--[@CR13]\]. Finally, the use of multilevel modeling helped us to separate neighborhood-level and individual-level effects and allowed for consideration of both random and fixed effects.

Conclusion {#Sec11}
==========

Neighborhood-level SES was modestly associated with statin medication rates in MI patients and this association was no longer significant after adjusting for individual-level sociodemographic factors. These findings raise important clinical and public health concerns, and indicate that individual-level approaches may be most important in health care policies regarding statin medication in MI patients.

Highlight {#Sec12}
=========

This is the first study to determine whether neighborhood socioeconomic status is associated with statin medication rates in myocardial infarction (MI) patients.Low neighborhood-level socioeconomic status was significantly associated with lower statin medication rates (odds ratio 0.80).After adjustment for individual-level socioeconomic characteristics and comorbidities, this association was no longer significant.Individual-level approaches may be most important in health care policies regarding statin medication in MI patients.
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